Search results for "CQ"

showing 10 items of 1801 documents

Decrease of CD4+ T Lymphocytes after myocardial infarction is related with extensive myocardial fibrosis

2013

Purpose: Myocardial fibrosis plays a potential role in left ventricular remodeling and patients' outcome. After myocardial infarction innate immune cells infiltrate infarcted area and replace necrotic tissue by fibrotic tissue. However the role of adaptive immunity, especially T cells, has not yet been investigated in this scenario. Methods: We studied 94 patients with a first STEMI treated with percutaneous revascularization. Leucocyte subsets and a wide variety of lymphocyte subtypes were determined in peripheral blood 24 h after reperfusion by means of flow cytometry. Infarct size and cardiac fibrosis were measured by late enhancement Cardiac Magnetic Resonance (CRM) 1 week and 6 months …

medicine.medical_specialtyCardiac fibrosisbusiness.industryLymphocyteInfarctionmedicine.diseaseAcquired immune systemmedicine.anatomical_structureImmune systemFibrosisInternal medicinecardiovascular systemmedicineCardiologyMyocardial fibrosisCardiology and Cardiovascular MedicineVentricular remodelingbusinessEuropean Heart Journal
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct

Outpatient Treatment And Community Acquired Pneumonia (CAP): A Comparative Study With Hospital Admission

2011

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industryEmergency medicineHospital admissionmedicineMedical emergencymedicine.diseasebusinessC55. RISK FACTORS, PROGNOSIS, AND MANAGEMENT OF BACTERIAL PNEUMONIA
researchProduct

Antibiotic Use Prior To Admission And Community Acquired Pneumonia (CAP)

2011

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industryMedicineAntibiotic usebusinessIntensive care medicinemedicine.diseaseC55. RISK FACTORS, PROGNOSIS, AND MANAGEMENT OF BACTERIAL PNEUMONIA
researchProduct

Validation Of Ecurb In Community-Acquired Pneumonia: Which Gold Standard Are We Talking About?

2011

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industryMedicineGold standard (test)businessIntensive care medicinemedicine.diseaseC55. RISK FACTORS, PROGNOSIS, AND MANAGEMENT OF BACTERIAL PNEUMONIA
researchProduct

Accuracy Of Non-Invasive Methods For The Evaluation Of Oxygenation Status In Community-Acquired Pneumonia: Comparison Of PaO2/FiO2 Calculated From Se…

2012

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industryNon invasiveMedicineOxygenationbusinessmedicine.diseaseIntensive care medicineA54. ASSESSING SEVERITY OF DISEASE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
researchProduct

Community Acquired Pneumonia (CAP) With PSI V Admitted To Intensive Care Unit (ICU). Comparative Study

2010

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industrylawmedicineIntensive care medicinebusinessmedicine.diseaseIntensive care unitlaw.inventionB50. RESPIRATORY TRACT INFECTIONS: DIAGNOSIS AND PROGNOSIS
researchProduct

Long-term Prognostic Value Of CURB-65 In Community-acquired Pneumonia

2010

medicine.medical_specialtyCommunity-acquired pneumoniabusiness.industrymedicinemedicine.diseaseIntensive care medicinebusinessValue (mathematics)CURB-65Term (time)B50. RESPIRATORY TRACT INFECTIONS: DIAGNOSIS AND PROGNOSIS
researchProduct

Snapshot multi-spectral-line imaging for applications in dermatology and forensics

2019

Performance of multi-spectral imaging critically depends on image acquisition time and working spectral bandwidths. Ultimate performance can be achieved if a set of monochromatic (single-wavelength) spectral images is obtained by a single snapshot - a technique provisionally called “snapshot multi-spectral-line imaging” or SMSLI. The SMSLI principle and the developed prototype devices for 3, 4 and 5 spectral line snapshot imaging are described. Two potential practical applications of SMSLI are discussed – for fast mapping of the main in-vivo skin chromophores and for detection of counterfeit banknotes and documents.

medicine.medical_specialtyComputer sciencebusiness.industryComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONMulti spectralSpectral lineSpectral imagingmedicineImage acquisitionSnapshot (computer storage)Computer visionMonochromatic colorArtificial intelligencebusinessImaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues XVII
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct